| Jun 12 |
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
|
| Jun 10 |
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
|
| Jun 4 |
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis
|
| May 9 |
Surrozen Non-GAAP EPS of -$4.24
|
| May 9 |
Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
|
| May 8 |
Surrozen Provides First Quarter 2024 Financial Results and Business Update
|
| Apr 18 |
Surrozen files to sell 1.09M shares of common stock for holders
|
| Apr 1 |
Surrozen announces up to $192.5M private placement of securities priced at-the-market under Nasdaq rules
|
| Apr 1 |
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
|
| Apr 1 |
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
|
